Verve names sec­ond PC­SK9 can­di­date; Ex­sci­en­tia picks an­oth­er AI-cre­at­ed mol­e­cule for clin­ic

Boston-based Verve Ther­a­peu­tics has un­veiled its sec­ond PC­SK9-tar­get­ing pro­gram.

The biotech an­nounced the can­di­date, dubbed Verve-102, as part of its wider third-quar­ter fi­nan­cial re­sults. Verve …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER